EGFR, ALK, ROS1 and TP53 gene mutations were negative, programmed death ligand 1 (PD‐L1) expression was <1%, and the tumour mutational burden (TMB) was 28.3 mut/Mb. The gene discussed is CD274; the disease is neoplasm.